LYME DISEASE IS A VECTOR-BORNE, MULTISYSTEM INFLAMMATORY DISEASE CAUSED BY THE SPIROCHETE *Borrelia burgdorferi*, WHICH IS TRANSMITTED TO HUMANS BY THE BITE OF TICSKS OF THE *Ixodes ricinus* COMPLEX. *B. burgdorferi* IS DIVIDED INTO AT LEAST 11 SPECIES INCLUDING *Borrelia garinii*. *B. garinii* IS ONE OF THE TWO MAJOR STRAINS FOUND IN EUROPE AND IS GRAM-NEGATIVE AND HELICAL IN SHAPE. THE NEUROLOGICAL SYMPTOMS OF LYME DISEASE SUCH AS BACK AND LEG PAINS AND PARTIAL FACIAL PARALYSIS ARE CAUSED BY *B. garinii*, WHICH USUALLY RESIDES IN THE CEREBROSPINAL FLUID OF INFECTED MAMMALS. OUTER SURFACE PROTEIN A AND THE CELL BOUND PROTEOGLYCANS ARE INVOLVED IN THE ATTACHMENT OF *B. garinii* TO NEURONAL CELLS. PATIENTS INFECTED WITH *B. garinii* TEND TO BE OLDER, WITH SKIN LESIONS OFTEN LOCATED ON THE TRUNK. *B. garinii* HAS A SHORTER INCUBATION TIME COMPARED WITH OTHER *Borrelia* STRAINS, AND IT IS MORE OFTEN ASSOCIATED WITH CERTAIN LOCAL SYSTEMIC SYMPTOMS AND ABNORMAL LIVER FUNCTION.

REFERENCES


SOURCE

*Borrelia burgdorferi garinii* (Bg14) is a mouse monoclonal antibody raised against bacterial lysates of *Borrelia burgdorferi garinii* origin.

PRODUCT

Each vial contains 100 µg IgG1 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

*Borrelia burgdorferi garinii* (Bg14) is recommended for detection of *Borrelia burgdorferi garinii* by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

STORAGE

Store at 4°C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.